Literature DB >> 17396131

Adenosine, an endogenous distress signal, modulates tissue damage and repair.

B B Fredholm1.   

Abstract

Adenosine is formed inside cells or on their surface, mostly by breakdown of adenine nucleotides. The formation of adenosine increases in different conditions of stress and distress. Adenosine acts on four G-protein coupled receptors: two of them, A(1) and A(3), are primarily coupled to G(i) family G proteins; and two of them, A(2A) and A(2B), are mostly coupled to G(s) like G proteins. These receptors are antagonized by xanthines including caffeine. Via these receptors it affects many cells and organs, usually having a cytoprotective function. Joel Linden recently grouped these protective effects into four general modes of action: increased oxygen supply/demand ratio, preconditioning, anti-inflammatory effects and stimulation of angiogenesis. This review will briefly summarize what is known and what is not in this regard. It is argued that drugs targeting adenosine receptors might be useful adjuncts in many therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396131     DOI: 10.1038/sj.cdd.4402132

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  260 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Adenosine signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans development.

Authors:  Yunge Zhao; Damien J LaPar; John Steidle; Abbas Emaminia; Irving L Kron; Gorav Ailawadi; Joel Linden; Christine L Lau
Journal:  J Heart Lung Transplant       Date:  2010-12       Impact factor: 10.247

3.  Purinergic signaling: a fundamental mechanism in neutrophil activation.

Authors:  Yu Chen; Yongli Yao; Yuka Sumi; Andrew Li; Uyen Kim To; Abdallah Elkhal; Yoshiaki Inoue; Tobias Woehrle; Qin Zhang; Carl Hauser; Wolfgang G Junger
Journal:  Sci Signal       Date:  2010-06-08       Impact factor: 8.192

4.  A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Alexander Vezeridis; Haralambos Gavras; Dan Yang; Vassilis Zannis; Katya Ravid
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

5.  A2B adenosine receptor-mediated induction of IL-6 promotes CKD.

Authors:  Yingbo Dai; Weiru Zhang; Jiaming Wen; Yujin Zhang; Rodney E Kellems; Yang Xia
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

6.  A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo.

Authors:  Shannon H Carroll; Nathan A Wigner; Nitin Kulkarni; Hillary Johnston-Cox; Louis C Gerstenfeld; Katya Ravid
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

7.  Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease.

Authors:  Hiroki Tsukamoto; Petya Chernogorova; Korcan Ayata; Ulrike V Gerlach; Ankur Rughani; Jerry W Ritchey; Jayanthi Ganesan; Marie Follo; Robert Zeiser; Linda F Thompson; Marco Idzko
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

8.  Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation.

Authors:  Sergey Ryzhov; Bong Hwan Sung; Qinkun Zhang; Alissa Weaver; Richard J Gumina; Italo Biaggioni; Igor Feoktistov
Journal:  Purinergic Signal       Date:  2014-03-01       Impact factor: 3.765

9.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.

Authors:  Yuliia Kaljas; Chengqian Liu; Maksym Skaldin; Chengxiang Wu; Qing Zhou; Yuanan Lu; Ivona Aksentijevich; Andrey V Zavialov
Journal:  Cell Mol Life Sci       Date:  2016-09-23       Impact factor: 9.261

10.  Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.

Authors:  Li Li; Liping Huang; Hong Ye; Steven P Song; Amandeep Bajwa; Sang Ju Lee; Emily K Moser; Katarzyna Jaworska; Gilbert R Kinsey; Yuan J Day; Joel Linden; Peter I Lobo; Diane L Rosin; Mark D Okusa
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.